À retenir
Across 30 randomised trials with 1,827 adults with type 2 diabetes, probiotics lowered fasting blood glucose (SMD -0.331, 95% CI -0.424 to -0.238) and HbA1c (SMD -0.421, 95% CI -0.584 to -0.258) compared with placebo. These are standardised effects with no clinical units given in the abstract, so the real-world size of the change in HbA1c is not stated.
Study design
Revue des preuves
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Probiotics have been proposed as an add-on for blood sugar control in type 2 diabetes. The authors pooled randomised trials to test whether probiotic supplements improve fasting glucose, insulin, HbA1c and insulin resistance compared with placebo.
Population et méthode
Systematic review and meta-analysis of randomised clinical trials of probiotics in type 2 diabetes, searched in PubMed, Web of Sciences, Embase and Cochrane Library from inception to October 2022. Effects were expressed as standardised mean differences (SMD) with 95% confidence intervals for fasting blood glucose (FBG), insulin, haemoglobin A1c (HbA1c) and the homeostasis model of assessment of insulin resistance (HOMA-IR). Subgroup analyses were run by ethnicity, baseline body mass index (BMI), probiotic type and form. The abstract does not report risk-of-bias findings or heterogeneity.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 130 randomised trials including 1,827 patients were identified.
- 2Compared with placebo, probiotics lowered FBG (SMD -0.331, 95% CI -0.424 to -0.238, P < 0.001) and HbA1c (SMD -0.421, 95% CI -0.584 to -0.258, P < 0.001).
- 3Insulin (SMD -0.185, 95% CI -0.313 to -0.056, P = 0.005) and HOMA-IR (SMD -0.224, 95% CI -0.342 to -0.105, P < 0.001) also fell.
- 4Effects were larger in subgroups of Caucasians, high baseline BMI (≥30.0 kg/m2), Bifidobacterium and food-type probiotics (P for subgroup < 0.050).
Limites et incertitude
- 1Results are in standardised units, so the abstract does not show how many percentage points of HbA1c or mg/dL of glucose were lost, and standardised effects of this size are modest.
- 2The subgroup differences are secondary analyses, and the abstract does not report the number of trials in each subgroup.
- 3Trials differ in probiotic strain, dose and form, and the abstract does not describe study duration, quality or heterogeneity.
- 4This reading is based on the abstract only.
Mise en perspective
Probiotics may be a small add-on for blood sugar in type 2 diabetes, but they are not a replacement for prescribed treatment, diet and activity. The abstract does not identify a best product or dose. Talk with your diabetes care team before adding supplements or changing treatment.
Vos données
HbA1c is a lab test usually repeated every few months, while fasting glucose can come from a meter or a continuous glucose monitor. If you try a supplement with your clinician's agreement, compare fasting glucose and CGM trends before and after under similar eating, sleep and activity patterns, rather than reading single days.
Comprendre ce type de preuve
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Objective
This systematic review and meta-analysis study aimed to evaluate the effectiveness of probiotics supplementation on glycaemic control in patients with type 2 diabetes mellitus (T2DM) based on the data from the randomised clinical trials (RCTs).
Methods
PubMed, Web of Sciences, Embase, and Cochrane Library were searched from the inception to October 2022, and RCTs about probiotics and T2DM were collected. The standardised mean difference (SMD) with 95% confidence interval (CI) was used to estimate the effects of probiotics supplementation on glycaemic control related parameters, e.g. fasting blood glucose (FBG), insulin, haemoglobin A1c (HbA1c), and homeostasis model of assessment of insulin resistance (HOMA-IR).
Results
Thirty RCTs including 1,827 T2MD patients were identified. Compared with the placebo group, the probiotics supplementation group had a significant decrease in the parameters of glycaemic control, including FBG (SMD = - 0.331, 95% CI - 0.424 to - 0.238, P_(effect) < 0.001), insulin (SMD = - 0.185, 95% CI - 0.313 to - 0.056, P_(effect) = 0.005), HbA1c (SMD = - 0.421, 95% CI - 0.584 to - 0.258, P_(effect) < 0.001), and HOMA-IR (SMD = - 0.224, 95% CI - 0.342 to - 0.105, P_(effect) < 0.001). Further subgroup analyses showed that the effect was larger in the subgroups of Caucasians, high baseline body mass index (BMI ≥ 30.0 kg/m^(2)), Bifidobacterium and food-type probiotics (P_(subgroup) < 0.050).
Conclusion
This study supported that probiotics supplementation had favourable effects on glycaemic control in T2DM patients. It may be a promising adjuvant therapy for patients with T2DM.
Sources et attribution
The effects of probiotics supplementation on glycaemic control among adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials.
Li G, Feng H, Mao XL, Deng YJ, Wang XB, Zhang Q, Guo Y, Xiao SM.
Journal of translational medicine · 2023-07-06
DOI: 10.1186/s12967-023-04306-0 ↗PubMed · 37415167 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

